AGI Therapeutics plc
Manufacturing · 1-10 Employees
View Company Info for Free
Overview
Phone Number
(443) 285-0095Website
www.agitherapeutics.comRevenue
<$5 MillionIndustry
About AGI Therapeutics plc
Is AGI Therapeutics plc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if AGI Therapeutics plc is spiking on competitors!
AGI Therapeutics plc, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once AGI Therapeutics plc has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if AGI Therapeutics plc had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AGI Therapeutics plc
Product Launch: Get notified when AGI Therapeutics plc launches new products
Earning: See what the market has to say on AGI Therapeutics plc recently announced quarterly report
Check if AGI Therapeutics plc has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
AGI Therapeutics plc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AGI Therapeutics plc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AGI Therapeutics plc.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AGI Therapeutics plc
AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, including treatments for conditions which qualify for Orphan drug status. The Company's lead programme, AGI-350, is being developed to treat a significant unmet medical need in t... Read More